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The SHAPES strategy: an NMR-based approach for lead
generation in drug discovery
Jasna Fejzo, Christopher A Lepre, Jeffrey W Peng, Guy W Bemis, Ajay,
Mark A Murcko and Jonathan M Moore
Background: Recently, it has been shown that nuclear magnetic resonance
(NMR) may be used to identify ligands that bind to low molecular weight protein
drug targets. Recognizing the utility of NMR as a very sensitive method for
detecting binding, we have focused on developing alternative approaches that
are applicable to larger molecular weight drug targets and do not require
isotopic labeling.
Results: A new method for lead generation (SHAPES) is described that uses
NMR to detect binding of a limited but diverse library of small molecules to a
potential drug target. The compound scaffolds are derived from shapes most
commonly found in known therapeutic agents. NMR detection of low (µM–mM)
affinity binding is achieved using either differential line broadening or transferred
NOE (nuclear Overhauser effect) NMR techniques. 
Conclusions: The SHAPES method for lead generation by NMR is useful for
identifying potential lead classes of drugs early in a drug design program, and is
easily integrated with other discovery tools such as virtual screening, high-
throughput screening and combinatorial chemistry.
Introduction
In a target-directed drug discovery program, many differ-
ent strategies may be applied in the search for a clinical
candidate. Although these approaches to drug discovery
might follow significantly different pathways of optimiza-
tion to a highly potent and bioavailable drug molecule,
they all share a common origin: they must begin with a
lead compound. Because many properties of the final
compound (e.g. target affinity, solubility, ease of synthe-
sis, toxicity and bioavailability) are highly dependent on
those of the initial lead, the methods by which leads are
identified in the early stages could significantly impact the
success of the project in the latter stages. 
How, then, are leads chosen? A lead molecule may typi-
cally be a known drug molecule, or analog of a known
drug. Alternatively, if the target is an enzyme, the lead
may be a substrate or substrate analog. In many cases, a
lead is discovered simply by random screening of
commercially available or proprietary compound libraries.
However, many potential problems may arise using the
above strategies. For example, starting with a known drug
may not lead to sufficient diversity in the final class of
compounds to describe them as unique intellectual prop-
erty. Starting with a bioactive natural product may necessi-
tate the design of high molecular weight analogs, with
poor synthetic accessibility and difficult scale-up prob-
lems. Alternatively, using random screening to generate
leads might result in a novel class of compounds, but the
class might not contain a practical range of synthetically
accessible compounds such that problems related to solu-
bility, bioavailability or toxicity may be overcome without
overly compromising potency. 
In cases where random screening is used to generate
leads early in a drug design program, several approaches
may be taken. A brute force approach is to screen very
large (>100,000) numbers of compounds, and hope to
identify a potent binder or inhibitor of the drug target,
then optimize. A more rational approach is to use infor-
mation-driven methods for virtual screening of databases
to select a smaller subset of compounds for screening
[1,2]. For example, a typical protocol might employ simi-
larity-searching or docking methods (in a structure-based
program) to search available databases for good screening
candidates. A subset of representative compounds is
then assayed for binding or inhibition. Weak binders or
inhibitors become leads for iterative structure-based drug
design or SAR (structure–activity relationship)-based opti-
mization, depending on whether structural information
regarding the target is available. However, when one
uses subset selection methods to attempt to represent
several hundred thousand compounds with several thou-
sand, several questions arise. Have a sufficient number
of compounds been chosen? Have the correct subset of
compounds been chosen to represent a much larger
group in a compound space representing all commer-
cially available compounds? And is sufficient diversity
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represented in these compounds? If one now considers
the possibility of filtering through a virtual library con-
taining over 109 compounds, the problem becomes even
more challenging. Clearly, at this stage, more information
to guide the selection of compounds for screening would
be extremely beneficial.
We have developed a novel approach to assist in the
process of early lead generation. Using simple nuclear mag-
netic resonance (NMR) techniques to assess binding, we
screen a small but diverse library of low molecular weight,
soluble compounds — the ‘SHAPES library’ — against the
target of interest. The library is composed largely of mol-
ecular shapes that represent frameworks most commonly
found in known drug molecules [3]. Weakly binding
(Kd ~µM–mM) hits, many of which would be missed in a
standard enzymological assay, are then used to bias the fil-
tering of large chemical databases or virtual libraries, and
select a larger group of compounds for purchase or synthe-
sis followed by high-throughput screening.
To demonstrate the feasibility of such an approach, we
have screened the SHAPES library against a number of
drug targets. We were able to rapidly differentiate
between binding and nonbinding compounds in small
noninteracting mixtures, demonstrating the utility of the
method with several enzyme targets, including the p38
MAP kinase, a 42 kDa protein, and inosine-5′-monophos-
phate dehydrogenase (IMPDH), a multimeric enzyme
target of 224 kDa.
Results
Library design
Our goal was to design a library of small molecules that
optimized a large number of factors at once (cost, syn-
thetic accessibility, solubility, separation of NMR peaks
and diversity). The strength of such an approach is that a
set of simple drug-like molecules provides an array of
binding information for almost any target. These mol-
ecules and their derivatives translate into hits whose
chemistry tends to be well understood and whose physi-
cal properties tend to be desirable for lead compounds.
The SHAPES concept
Design of the SHAPES library is based to a large extent
on previously published work, in which commercially
available therapeutics were examined for common chemi-
cal features that made these compounds ‘druglike’ [3]. In
this study, all drug molecules were broken down into
systems consisting of rings, linkers and sidechains. The
union of cyclic arrays of atoms in a molecule (‘rings’), and
those atoms that directly connect them (‘linkers’) were
classified as ‘frameworks’. An analysis of the comprehen-
sive medicinal chemistry (CMC) database (MDL Informa-
tion Systems, San Leandro, CA, v.94.1) indicated that
1179 simple frameworks described the 5120 relevant
entries, and that surprisingly, only 32 different frame-
works, or ‘shapes’, described ~50% of all known drugs.
When atom type and bond order were incorporated into
the analysis, 2506 complex frameworks described the 5120
entries, and 41 frameworks described 24% of all drugs. For
details of the analyses, see the original work of Bemis and
Murcko [3]. In this paper, the terms ‘complex framework’
and ‘scaffold’ are used interchangeably.
One may extend this type of analysis further. Drug
sidechains are the linear arrays of atoms connected to mol-
ecular frameworks. A similar study of the CMC database
revealed a set of preferred sidechains found in known ther-
apeutics (details to be presented elsewhere). The details of
the juxtaposition of sidechains and frameworks are likely to
be important in many cases for drug binding. The results of
the drug framework and sidechain analyses may therefore
be used together as a general method to select a set of com-
mercially available compounds with drug-like character.
Compound selection from CMC-based frameworks
All library molecules were selected on the basis of frame-
works in the CMC database. First, a semi-automated
approach was used that combined the most frequently
occurring drug frameworks of the 41 mentioned above
with the 30 most common drug sidechains (see the Sup-
plementary material section). A substructure search was
done by searching the available chemicals directory (ACD)
database (MDL Information Systems, San Leandro, CA;
ACD98.2) for each molecular framework, leaving all
sidechain valences open. The resulting hit list was then fil-
tered to select examples that contained only sidechains
specified by our analysis. These examples were biased
towards molecules that in our estimation would have high
aqueous solubility. We assumed that solubility is corre-
lated with the number of heteroatoms, so all of the chosen
molecules contained at least one nitrogen or oxygen.
Approximately one third of the 41 frameworks were not
used because of either their inherent synthetic complexity
or the absence of sufficiently soluble analogs in the ACD.
In our current library, approximately half were selected as
described above. The remainder were chosen to represent
drug classes that occur frequently in the CMC (MDL
Information Systems, San Leandro, CA; CMC3D98.1) but
are not among the 41 most common frameworks.
The current set of frameworks from which the ‘SHAPES’
library is derived is shown in Figure 1. All library com-
pounds were commercially available, soluble and non-
aggregated in water at 1 mM, chemically and isomerically
pure, and nonreactive. Molecular weights of library com-
pounds are in the range 68–341 Da with an average of
194 Da, contain 6–22 heavy atoms, and have a calculated
logP of –2.2 to 5.5. For NMR screening analysis they must
also yield a simple, well-resolved 1H NMR spectrum, and
contain at least two protons within 5 Å of one another. 
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Presently, the SHAPES library consists of a pool of 132
compounds, from which a subset is screened depending
on solubility considerations at a given pH. For screens in
standard buffers (e.g. phosphate at pH 7.0 and Tris at
PH 8.0), approximately 120 compounds are used.
Detection of binding by NMR — theory of exchanging
systems
The values of certain NMR observables, such as trans-
verse and longitudinal relaxation rates (R1 and R2), the
nuclear Overhauser effect (NOE), and the diffusion
coefficient, are highly dependent on molecular size and
shape. The NMR parameters for a small molecule are
therefore exquisitely sensitive to interactions with larger
molecules. Changes in line widths, relaxation rates and
NOE values may be used to characterize and quantitate
the binding of a small molecule to a larger target mol-
ecule such as a protein [4].
In a typical protein–ligand interaction there are three
species in equilibrium: the protein, E, the ligand, L and
the molecular complex EL:
(1)
The above equilibrium is described by the dissociation
constant, Kd = koff/kon, where koff is the off rate, or rate of
dissociation of ligand from the protein–ligand complex,
and kon is the on rate, or rate constant for association of the
ligand with the protein. The diffusion-limited on rate is
often estimated at 108 M–1 s–1. Ligands that bind tightly
(e.g. Kd ~10–9 M; koff ~10–1 s–1) are considered to be in
‘slow exchange’ on the NMR time scale, whereas ligands
that bind very weakly (e.g. koff >103 s–1) are considered to
be in ‘fast exchange’. 
Using the notation of Ni [4], and describing any NMR
observable as P, the magnitude of the effect observed for a
small-molecule ligand resonance (Pobs) exchanging
between the free and bound states with a receptor mol-
ecule is a superposition of the parameters due to both the
free (Pfree) and bound states (Pbound). Pobs is a function of
protein [E] and ligand [L] concentration, the ratio of
ligand to target, and Kd:
Pobs = (1–pb)Pfree + pb(Pbound) (2)
where pb is the fraction of ligand in the bound state. For
example, if [L] << [E], ligands in extremely slow
exchange on the NMR time scale remain bound during
the entire process of nuclear spin excitation and
relaxation. In this case, pb ~1, and Pobs~Pbound. The small
molecule will then have R1, R2 and NOE values
characteristic of the entire protein–ligand complex.
Ligands in fast exchange, however, come off the protein
tens or hundreds of thousands of times before the signals
relax. In this case pb will be very small, Pobs ~Pfree, and
the resonances will display parameters closer to those of
the free ligand. Note that we use a protein here as an
example of a typical target, but targets may be any
molecule that interacts with the ligand, such as DNA,
RNA or another biomolecule.
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Figure 1
Molecular frameworks used for library
selection. Attachment points for sidechains
are indicated by single electrons or lone pairs.
‘X’ represents a C, N, O or S atom.
Frameworks in the top three rows were 
found in the original analysis [3]. Additional
frameworks are shown in the bottom two
rows, as well as in the third row, depending
on the identity of atom X.
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Large versus small proteins
Binding studies using NMR are often performed by mea-
suring ligand line broadening in the 1H spectrum of a
ligand–protein mixture. Line broadening for ligand reso-
nances in an exchanging complex arises from T2obs relax-
ation (T2obs = 1/R2obs) associated with molecular
tumbling, as well as additional contributions resulting
from differences in the chemical shift between the free
and bound ligand. Qualitatively, the most significant line
broadening is observed for a ligand:protein ratio of 1:1 or
less, where a higher percentage of the ligand is bound to
protein. In practice, when monitoring changes in ligand
parameters to assess binding, it is useful to have ligand
concentrations >0.2 mM, which ensures adequate signal
to noise in the NMR spectra over a short experiment
time. In most cases, however, the target protein will be
the limiting reagent, so a tradeoff exists between
increased protein consumption with greater sensitivity,
and low protein consumption with reduced sensitivity. 
Of course, the sensitivity of simple differential line broad-
ening (DLB) measurements is inherently dependent on
the molecular weight of the target (Figures 2,3). Figure 2
shows the best-case scenario for line-broadening mea-
surements. The target protein IMPDH is a 224 kDa
multimeric enzyme essential for de novo guanine
nucleotide biosynthesis. The furthest downfield compo-
nent exhibits a line width at half height (LW½) of 3 Hz.
The ligand at the same concentration in the presence of
100 µM IMPDH (Ki ~60 µM) shows significant line broad-
ening (LW½ = 30 Hz). For smaller target systems (e.g.
20–60 kDa), observed line-broadening effects are not
always as pronounced. The one-dimensional (1D) spectra
of two small-molecule compounds in the presence
(ligand:protein = 5:1) and absence of p38 are shown in
Figure 3. Noticeable line-broadening effects and attenua-
tion of fine structure are observed for one of the com-
pounds, 2-phenoxybenzoic acid (Kd ~70 µM). For
compounds that bind with weaker affinity (Kd ~1–10 mM),
however, it is difficult to obtain reproducible and reliable
line-broadening data with smaller targets, even under the
most favorable ligand:protein ratios.
Despite the difficulties in obtaining reliable line-broaden-
ing data, it is often possible to determine qualitatively
whether a molecule is binding the target by looking for
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Figure 2
1D-1H spectra of free ligand (1, lower spectrum) and 1 in the presence
of IMPDH (upper spectrum). The significant line broadening observed
in the presence of the enzyme indicates binding of the small molecule.
Line widths at half height for the furthest downfield component of
1 (leftmost peak) are 3 Hz (lower trace) and 30 Hz (upper trace). The
sample contained 1 mM ligand + 100 µM IMPDH in 25 mM d-TRIS
pD* = 8.4, 300 mM KCl, 5% d-glycerol, 5 mM DTT. 1D spectra were
collected at 277 K with 1 s low power presaturation of the residual
HDO signal, using a Bruker DRX-800 spectrometer.
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Figure 3
1D-1H spectra of (a) a mixture of two ligands and (b) the mixture of the
ligands in the presence of p38 MAP kinase. Resonances from nicotinic
acid (left structure) and 2-phenoxy benzoic acid (right structure) are
marked with solid and dashed arrows, respectively. The peak at
7.2 ppm consists of overlapping resonances from both compounds.
Line broadening, suppression of fine structure, and attenuation of ligand
resonance peak height due to relaxation filter in the bottom spectrum
indicate 2-phenoxy benzoic acid binds to p38, whereas nicotinic acid
does not. The sample contained 1 mM ligands, 0.2 mM p38 MAP
kinase, 25 mM deutero-Tris, 10% deutero-glycerol, 20 mM deutero-DTT
at pD* = 8.4. Experiments were carried out at 278 K. 1D NOESY
spectra were collected with 16 K data points, 128 transients and a
relaxation delay of 3 s. A relaxation filter was used after the preparatory
delay to attenuate broad resonances arising from the protein. 
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changes in intensities of ligand peaks in the presence of
the target versus the free state in concentration-matched
relaxation-filtered spectra. Relaxation-filtering elements
are routinely used in NMR pulse sequences to suppress
resonances from the protein (see the Materials and
methods section). Reductions in peak heights are regu-
larly observed for compounds that bind in the several
hundred micromolar to millimolar range. These spectral
changes are apparent from simple inspection of the data,
or can be quantitated using NMR difference methods, as
described by others [5]. It is difficult to assess accurately
relative affinities of binding using these methods,
however, because line broadening arises because of both
differences in T2 and chemical shift between the free and
bound states of the ligand. Line broadening can therefore
occur to differing magnitudes for two ligands binding to
the same target with the same affinity, as well as for differ-
ent proton sites within the same ligand molecule. 
To avoid these problems, we have relied on the two-
dimensional (2D) transferred NOE experiment (tNOE or
tNOESY) — a qualitative, but extremely reliable and sen-
sitive diagnostic for binding. The tNOE experiment is a
well-known NMR technique commonly used for deter-
mining the bound conformations of small molecules
undergoing rapid exchange with a protein target. Here,
however, its utility is in determining whether one of a
mixture of compounds binds to a target. The 2D tNOE
spectrum of small molecules in a mixture without protein
exhibit very weak NOE cross peaks, with sign opposite to
those of the diagonal peaks (Figure 4). In the presence of
the protein, cross peaks of ligands that do not bind the
target maintain phase opposite to that of the diagonal
peaks. Ligands that bind to the protein, however, will
transiently adopt the same rotational correlation time (or
tumbling time) as the protein during their bound life-
times. As the exchange process occurs many times before
the NMR signal dies, strong NOEs built up by the ligand
in the bound state are transferred to the easily detectable
1H NMR signals of excess free ligand, and the sign of the
cross peaks change such that they are the same as the sign
of diagonal peaks (Figure 4). These spectral changes allow
the ligands that bind and those that do not to be un-
ambiguously distinguished. Another group [6] has
reported the use of tNOE methods in a similar approach
to examine binding of a library of oligosaccharides to a
protein target.
It is clear from the discussion above that large proteins
(MW >60 kDa) represent the best case scenario for the
automated screening of compound libraries using NMR,
because 1D spectra at high ligand:protein ratio may be
collected in minutes using a robotic sample changer. Reli-
able data may also be collected on smaller targets,
although in a longer time period, as long as 2D tNOE
methods are used.
Although the examples and discussion in the present
work pertain to protein targets, the discussion is equally
applicable to nucleic acids, protein–nucleic-acid com-
plexes, proteins in detergents or micelles, targets tethered
to beads, or even large subcellular structures.
Screening the SHAPES library
The basic strategy
The basic strategy of SHAPES screening is to use the
SHAPES library to represent drug-like scaffolds, then
assess binding of this limited library to a drug target using
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Figure 4
2D NOESY spectra of the same mixture of
ligands shown in Figure 3. Positive contours
are cyan and negative contours are green.
(a) Both ligands in the mixture without protein
present have weak negative cross peaks and
positive diagonal peaks. (b) In the presence of
the protein cross peaks remain opposite in
phase to the diagonal peaks for the downfield
resonances corresponding to nicotinic acid,
indicating this compound does not bind.
However, the sign of the upfield cross peaks
of 2-phenoxy benzoic acid is the same as that
of the diagonal peaks, indicating this
compound binds to the protein. The peak at
7.2 ppm consists of overlapping resonances
from both compounds (see Figure 3 with 1D
spectra) and thus both positive and negative
cross peaks are found at this frequency. 2D
NOESY spectra were collected with 400 t1
increments and 2 K complex points in t2, with
mixing times of 50 and 200 ms, relaxation
delay of 2 s and 16 transients per t1
increment. A spin echo sequence after the
first proton pulse was used in the NOESY
experiments as a relaxation filter.
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simple NMR methods. In a typical NMR SHAPES screen,
a series of experiments are carried out, some before, and
others after, the actual determination of binding. Prelimi-
nary experiments include optimization of protein stability,
collection of reference spectra for the free ligands, and
design of mixtures. Following the SHAPES screen, experi-
ments may be performed to determine binding specificity
and affinity. Details of the experiments are described in
the following sections.
Prescreening protein stability
The NMR screening process exposes the target mol-
ecule to what most biologists would consider extreme
conditions. For example, a typical protocol for NMR
screening involves dissolving a protein in 500 µl of a suit-
able aqueous buffer at a concentration of 50–100 µM. Small
aliquots (e.g. 1 µl) of a concentrated stock of ligand in
deuterated dimethyl sulfoxide (DMSO) solution are added
to bring the final concentration of each ligand to ~1 mM.
Depending on how many ligands are used in a mixture,
the final DMSO concentration will be 0.2–1% or more.
Furthermore, adding acidic or basic ligand at these con-
centrations can significantly alter the pH of the screening
sample. Finally, the NMR samples are placed at room
temperature for significant time periods, both in the
sample changer rack and in the magnet. It is therefore
important to examine target protein stability and activity
as a function of organic solvent concentration, pH (buffer
type and buffer concentration), temperature and time
before a screen is carried out, so that valuable protein is
not unnecessarily lost, and to ensure that the protein
under these experimental conditions represents a viable
target for lead generation.
For most targets, we routinely employ the microdrop
protein screening method [7], which uses sub-milligram
quantities of protein to optimize sample conditions before
NMR screens are carried out. To assess the behavior of the
target protein in the presence of DMSO, microdrops con-
taining varying amounts of DMSO, with and without
common stabilizers present, are monitored visually. Protein
samples that appear stable under screening conditions are
assayed to ensure the target is still catalytically active or
otherwise competent. It is also important to assess whether
sample pH is affected by the presence of ligand mixtures
by measuring the pH of ligand mixtures in aqueous buffer
in the absence of the target. We have found empirically
that use of buffer concentrations much higher than needed
to maintain the pH of the protein (e.g. 100 mM) are
required to maintain the pH of the solution in the presence
of a mixture of 1 mM organic acids or bases.
Collecting reference data and mixture design
When confronted with the task of screening a library of
compounds using NMR, the question arises as to
whether one should screen single compounds or mixtures
of compounds. Several problems could arise in screening
mixtures of compounds. For example, any single com-
pound with a ten- or hundred-fold higher binding affinity
than others in the mixture would compete successfully for
most protein binding sites, particularly if ligands are
present in excess, and therefore one or more potential
binders might be missed. This problem is important
because simple modifications to a weak binding scaffold
might result in enormous increases in binding affinity at
later design stages, so missing potential scaffolds early in
the screening process might eliminate an entire compound
class from further development. Ultimately, a tradeoff
exists between resources (protein and spectrometer time),
and ease of data analysis and reliability. In our experience,
the competitive binding phenomenon described above has
never been problematic (as confirmed by enzymological
screening), probably because of the relatively small size
and intentionally weak affinities of the compounds in the
SHAPES library.
Another problem with using mixtures is spectral overlap.
If overlap is severe, analysis of 1D spectra might not be
possible, and analysis of 2D spectra would be difficult.
Using automated methods to search all possible combina-
tions of components, however, one can select mixtures in
which overlap is minimized, allowing a reliable line broad-
ening or tNOE analysis. We currently use mixtures of 1–4
compounds, although when using 2D tNOE spectroscopy
to identify binders, we have successfully used mixtures
containing up to 12 compounds (see the Materials and
methods section for details).
Screening the library and identifying target binders
The next step, screening the mixtures of SHAPES com-
pounds against the target, involves collecting either 1D or
both 1D and 2D tNOE NMR spectra for each mixture in
a separate sample with the target present. Ligand peaks in
the 1D and 2D spectra of the mixtures (with and without
the protein) are deconvoluted and assigned using the 1D
spectra of the individual components. As described above,
binding of components of the mixtures to the target is
revealed by differential line broadening or inversion of
the NOE cross peaks. Neither differential line broaden-
ing nor tNOE methods can distinguish specific binding
from nonspecific binding, so all ‘hits’ obtained using
NMR screening should be followed up with more rigorous
studies such as competition experiments to characterize
the specificity of the observed interaction.
Throughput
For a high-molecular-weight target (>60 kDa), the entire
SHAPES library may be screened in several hours, as only
1D spectra are necessary. For smaller targets (10–60 kDa),
which require both 1D line broadening and 2D NOE
spectra, the process requires several days. As the SHAPES
library is relatively small, the data collection time is not a
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limiting factor. In fact, in a typical screen it is useful to
collect tNOE spectra at several mixing times. Observing
differences in cross peak sign and intensity as mixing time
is increased allows a rough assessment of the relative
affinities of SHAPES hits for a given target.
Protein requirements
The quantity of protein required is significant when
compared with that of high-throughput enzymological
screening, but not necessarily when compared with a
structure-based drug-design program employing X-ray
crystallographic or NMR structural methods. Protein
requirements depend on the molecular weight of the
target. In initial studies, screens were carried out at
ligand:protein ratio of 10:1, using 100 µM protein and
1 mM ligand, but more recently we have found that
similar data quality and sensitivity may be obtained
using a ligand:protein ratio of 20:1, and all screens are
now carried out with protein concentrations of 50 µM.
For 32 mixtures averaging four compounds each, each
sample containing 0.5 ml 50 µM protein, screening the
SHAPES library would require: IMPDH (57 kDa sub-
units): (32 samples) × (0.5 ml) × (2.85 mg/ml) = 45.6 mg;
p38 (42 kDa): (32 samples) × (0.5 ml) × (2.1 mg/ml) = 33.6 mg.
If no deterioration of the protein is observed during the
course of the NMR measurements, the protein may be
recycled and used again for additional screens. Also, with
recent developments in NMR hardware, it is likely that
protein consumption could be reduced significantly by
using probes designed for smaller diameter tubes (2.5 mm),
using liquid handling systems for direct injection of samples
into a flow cell, or ‘tubeless’ NMR probe [8], or using a
high-sensitivity cryogenically cooled probe [9].
Determination of binding specificity
As mentioned previously, identification of ligand binding
in a SHAPES screen implies only that the compound
binds to the target. The observed binding could be spe-
cific, acting at either an active or a remote site, or non-
specific, with binding at many distinct sites. In the case of
multisubstrate enzymes as targets, the ‘active site’ will be
composed of several substrate binding sites, so defining a
compound as binding specifically to the active site could
also refer to any substrate subsite. When a compound is
present in a 10–20-fold excess over the target, it is not sur-
prising that the compound will bind to several sites on the
protein. For example, even a compound with nanomolar
affinity for a target will show a very high affinity for the
tight binding site, and once that site is saturated, weaker
(e.g. mM) binding might occur at one or more different
sites. We therefore routinely carry out simple competition
experiments for each hit in a SHAPES screen versus a
known high-affinity active-site-directed inhibitor. In these
studies, we define ‘specific binding’ as binding to a partic-
ular substrate site, for which the observed experimental
line broadening or tNOE effects can be significantly
attenuated or reversed in the presence of a known com-
pound or inhibitor with a high affinity for that site. In our
experience, most SHAPES hits are specific binders, but
show detectable contributions from nonspecific or nonac-
tive site binding components as well (data not shown). If
no site-specific inhibitor is known, one can attempt to
examine the dilution dependence of signal intensity or
percent NOE as described by Murali et al. [10].
Determination of binding affinity using NMR
Although in many cases relative binding affinities can be
assessed on the basis of observed line broadening and
tNOE data, it is often useful to determine binding con-
stants for SHAPES screening hits under NMR conditions.
Determining binding constants using NMR provides a
more quantitative analysis of relative binding affinities of
the SHAPES hits and establishes a basis for comparison
with Ki values determined by enzyme inhibition studies or
Kd values obtained with other biophysical methods, such as
fluorescence measurements. Traditional methods of deter-
mining a Kd value by NMR using T1, T2 or NOE measure-
ments (reviewed in [4]) are very time consuming, requiring
data measurements at a number of different ligand concen-
trations. These measurements actually involve two titra-
tions: the addition of ligand, and the incrementation of a
relaxation delay to determine, for example, R1 or R2 for
each concentration of ligand. The time required to collect
data with a reliable signal to noise ratio for longer relax-
ation delays makes a single Kd titration prohibitively long
(several days). If one now considers measuring a Kd value
for a series of screening hits, relaxation-based measure-
ments become completely impractical. To address this
problem, we have employed methods for Kd determination
based on NMR diffusion measurements [11].
It is well known that pulsed-field-gradient NMR experi-
ments can measure the diffusion coefficients of mol-
ecules in solution [12,13]. The diffusion coefficients of a
small molecule and of a protein can differ by an order of
magnitude or more. If the diffusion coefficient for a small
molecule is measured in the presence of a protein to
which it binds, its diffusion coefficient will be a weighted
average of the coefficients of the free and bound states of
the ligand, and will appear less than that measured for the
free ligand. The magnitude of this reduction is directly
related to the bound lifetime of the ligand on the much
more slowly diffusing protein, and may be used to calcu-
late the Kd value.
Figure 5 shows experimental pulsed-field-gradient NMR
diffusion data for 4-(3-pyridin-4-yl-1H-pyrazol-4-yl) pyrim-
idine (VRT-34,306) binding to p38 MAP kinase. The
decay curves show peak intensity versus K2 — a parameter
proportional to the square of the gradient amplitude — for
protein, free ligand and ligand in the presence of protein.
The dependence of peak height on gradient amplitude
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appears greatest for the free ligand, but is attenuated in
the presence of p38. Fitting of the decay curves yields
values for diffusion coefficients of the protein (Dbound),
the free ligand (Dfree), and the ligand in rapid exchange
between the free and bound states (Dobs). One can solve
for percentage of ligand bound (pb), and subsequently Kd
(described in the Materials and methods section). The
decay curve shown for VRT-34,306 gives a Kd value of
250 ± 90 µM for the p38 MAP kinase.
The advantages of determining binding constants using a
diffusion-based approach are clear. First, the Kd is deter-
mined under the same conditions as the NMR screening
(e.g. the same NMR concentrations and buffers), so the
NMR parameters observed by NMR screening may be cor-
related quantitatively with binding affinity. More impor-
tantly, the diffusion-based Kd determination requires no
titration. Titrations often demand the continued addition
of ligands dissolved in solvents hostile to the protein. As
ligand concentrations increase, so do the concentrations of
organic solvent, making the results of such titrations diffi-
cult to interpret. Eliminating the need for titrations also
reduces the time necessary for Kd measurements from
several days to several hours, making a series of measure-
ments on a number of different SHAPES hits feasible.
One must exercise caution, however, in interpreting these
data, as small errors in measurement of diffusion coeffi-
cients may lead to large errors in the calculated dissocia-
tion constant. For example, statistical errors of 5% in
measured diffusion coefficient can lead to errors of over
100% for certain ranges of binding constant (see the Mate-
rials and methods section for details). For this reason, Kd
values generated using diffusion methods should be con-
sidered approximate. Despite the uncertainties involved,
the relative speed and ease of carrying out these measure-
ments make them very useful for quickly discriminating
binding affinities of small molecules for large proteins and
for rank ordering binders to a common target.
Follow-up strategies
Selection of compounds for high-throughput screening
Effective follow-up of initial SHAPES hits is crucial if
information from weak NMR binders is ultimately to lead
to the discovery of potent drug leads (Figure 6). Our goal
is to use the initial SHAPES hits to guide subsequent
screening efforts and provide a starting point for structure-
based drug design. On the basis of SHAPES hits, follow-
up compounds may be chosen from in-house libraries or
purchased from a database of commercially available
chemicals, and screened using non-NMR-based enzymo-
logical or binding assays. In parallel, the data from
SHAPES screens may be used in conjunction with com-
putational techniques such as virtual screening to pur-
chase additional compounds or direct the synthesis of
combinatorial libraries. Other strategies, such as secondary
NMR screens to assess binding affinities of follow-up
compounds, soaking into crystals for characterization by
X-ray crystallography, or even completely NMR-based
methods similar to the ‘SAR by NMR’ technique [14–16],
are possible as well.
Several approaches may be employed to select com-
pounds for follow-up screening. For example, in a hypoth-
esis-based strategy the relative binding affinities of similar
SHAPES compounds are compared and used to construct
a hypothesis that correlates molecular features (such as
substitution pattern, location of H-bond donors and accep-
tors, or hydrophobic moieties) with binding. This ‘struc-
ture–affinity relationship’ is then used to construct a
library of compounds in which the original scaffold is
maintained, but the type and location of substituents is
systematically varied to test the putative pharmacophore.
Such a small and focused library will probably yield a high
percentage of hits, but is unlikely to dramatically improve
potency unless the original hit was already close to a
minimum in compound space. In a framework-based strat-
egy the original SHAPES scaffold is extended into larger
frameworks by adding common rings and linkers, while
the original scaffold core is allowed to vary within defined
similarity limits. Because the frameworks are larger than
the original compounds, they offer more potential sites of
interaction with the target and hence affinity may be
increased by several orders of magnitude. The overall hit
rate will probably be lower than for a narrowly focused
library, but the greater diversity allows better searching of
compound space.
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Figure 5
Diffusion curves showing peak integrals versus K2 (s/cm2 × 105). Peak
integrals for free 4-(3-pyridin-4-yl-1H-pyrazol-4-yl) pyrimidine, 4-(3-
pyridin-4-yl-1H-pyrazol-4-yl) pyrimidine in the presence of p38, and
p38 protein aromatic peaks are shown as open squares, filled
diamonds, and filled circles, respectively. K2 = γ2δ2Gz2(∆-δ/3) and
4γ2δ2Gz2(∆ + (5δ/3)) in the case of the p38 aromatic peaks and ligand
peaks, respectively. 
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Typically, both strategies are used in combination. As
some of the follow-up compounds will be relatively small
(particularly those most closely resembling the original
SHAPES hits), they are likely to be weak inhibitors. To
detect inhibition for these compounds, follow-up assays
may need to involve higher ligand concentrations than
those used for general screening so it is important to
remove from the follow-up libraries those compounds
most likely to give false positives in enzymatic assays.
We eliminate compounds that violate the ‘rule of five’
[17], contain inherently reactive or unstable functional
groups [18], or are dyes, stains, radioactive, and so on.
Only about 17% of the compounds in the ACD survive
this filtering process.
For SHAPES screens carried out thus far with six propri-
etary targets, we have observed hit rates of 10–20% with
libraries of 64–80 compounds. Of the initial SHAPES
binders, 30–40% were found to be inhibitors, with IC50
values between 150 µM and 5 mM. The NMR hits were fol-
lowed up using libraries of 100–300 compounds, screened at
30 µM in enzymatic assays. The hit rates for SHAPES-
derived follow-up compounds were 5–6%, which is 3–5-
fold higher than for non-SHAPES compounds in the same
assays (hit defined as ≥30% inhibition). The more potent
hits (1–13 µM) were soaked into enzyme crystals or co-
crystallized with target protein and the structures solved
crystallographically.
To compare hit rates for SHAPES with those for non-
SHAPES compounds using larger libraries, an indepen-
dent analysis was done using ‘virtual follow-up screens’.
HTS data for thousands of general screening compounds
were retrospectively analyzed to determine whether
compounds that contain SHAPES scaffolds with known
target affinity occurred more frequently as hits than com-
pounds containing either no SHAPES scaffold or
SHAPES scaffolds that did not bind the target. Com-
pounds containing scaffolds from SHAPES binders gave
a 2.5–4-fold greater frequency of hits at the 30% inhibi-
tion level, and an 8–10-fold higher frequency of hits at
50% inhibition.
Ligand design with SHAPES
The following example illustrates another approach
through which SHAPES screening may be employed to
identify a scaffold class, and how potent target directed
inhibitors might be designed on the basis of that scaffold
class. Figure 7 shows binding data from a SHAPES
screen of the p38 MAP kinase, along with data for
selected follow-up compounds. In an initial screen, the
simple imidazole core did not appear to bind p38.
Several tethered bicyclic compounds containing an imi-
dazole (or close derivative) and an aryl moiety (pyridyl,
phenyl or benzoic acid) showed weak binding. As imida-
zole by itself does not bind, this group may form a core
on which to fuse two of the tethered bicyclics or their
derivatives, creating tricyclic molecules with aryl deriva-
tives as sidechains. Two such tricyclic fusions of weak
binding fragments showed much tighter binding than
the bicyclic compounds, on the order of 200–300 micro-
molar versus 1–7 millimolar, respectively (Figure 7).
Further substitution of the imidazole results in com-
pounds similar to the trisubstituted imidazole shown in
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Figure 6
Flowchart indicating how information derived
from a SHAPES screen may be integrated
into the drug design process.
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Figure 7, a compound that binds too tightly to determine
a binding constant using NMR, but has a Ki value of
~200 nm in a p38 MAP enzyme assay [19]. This trisub-
stituted imidazole is in the same class of molecules
as the SmithKline Beecham 2,4,5-triarlyimidazoles,
including SB-203580, a potent and well-characterized
p38 inhibitor [20].
Although the fragments used in this example
were hand picked from simple, commercially available
databases, it is also straightforward to employ a combina-
torial chemistry strategy once a central scaffold is identi-
fied. Such an approach, coupled with HTS, takes
advantage of higher throughput technologies to identify
leads, rather than relying on slower, standard medicinal
chemistry approaches, or attempt ligand design entirely
using NMR.
Ligand design using NMR as a primary tool, such as in
the SAR by NMR method [14–16], is also possible with
the SHAPES library. Figure 8 shows the identification
of two ligands that bind simultaneously to different
sites on a target protein using simple homonuclear NMR
methods. The transferred NOE spectrum shows positive
cross and diagonal peaks for two compounds, VRT-
19,962 and VRT-13,578, indicating both compounds
bind to this 60 kDa enzyme drug target. In addition,
the two compounds show intermolecular NOEs, indi-
cating the two fragments are bound in close proximity
(<5 Å) on the target. Subsequent experiments indi-
cated unambiguously that both molecules were binding
simultaneously and that VRT-19,962 binding was
required before VRT-13,578 binding could occur. Such
information is very useful in the process of lead genera-
tion, but, in general, observation of these events is rather
fortuitous unless all possible combinations of SHAPES
hits are examined.
A hybrid approach, using ideas from both SAR by NMR
and SHAPES, may be used in an effort to optimize an
existing lead by replacing only a fragment of the lead. For
example, a binding core of a known inhibitor can be used
to saturate a subsite on the target, and the SHAPES
library can be screened to identify molecules that bind at
an adjacent subsite. Transferred NOEs between protons
on the different fragments should be observable if they
are in reasonable proximity and if the fragments are in the
appropriate exchange regime. This method may be useful
in overcoming undesirable physical chemical properties
of a lead compound resulting in poor bioavailability,
pharmacokinetic or toxicological profiles.
Discussion
We have described a general method for screening a library
of ligands for target affinity using NMR spectroscopy. The
NMR experiments are based on the well-known tech-
niques of differential line broadening and tNOE, and may
be applied to targets with no limitation on molecular
weight and no requirement for isotope labeling. NMR
SHAPES screening offers a complementary approach to
standard enzymological or ligand binding HTS. Although
enzymological techniques are superior when screening for
inhibitors that bind in the nanomolar to micromolar range,
the affinity of more weakly binding inhibitors will be below
the level at which inhibition can be reliably detected. In
addition, small-molecule cores that bind, but do not inhibit,
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Figure 7
An example showing how fusion of fragments
with a common scaffold can lead to a potent
inhibitor. Dissociation constants of the
compounds for p38 as determined by NMR
diffusion measurements are given below each
compound. Dissociation constants for
compounds marked with asterisks could not
be determined using diffusion methods. The
values given for the compounds shown in
green at the lower left are estimated from line
broadening and transferred NOE data, and
the value shown for the compound in magenta
at the lower right was determined
enzymatically [19].
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the enzymatic activity will also go undetected, eliminating
the possibility of designing molecules that take advantage
of binding to a remote site on the target. 
Although we have thus far examined only soluble protein
targets, one can envision these techniques being applied
to membrane-bound proteins in micelles or detergents,
nucleic acids, large subcellular structures, or even to
targets that have been chemically cross-linked to a solid
support. The methods described are extremely useful in
the early stages of a drug-design program, or alternatively
in a well-established program in search of second or third
generation compounds.
Comparison with other NMR-based screening techniques
It is useful to compare our SHAPES strategy with the ‘SAR
by NMR’ method, recently described by the Abbott group
[14]. SAR by NMR may best be described as a method for
primarily NMR-driven ligand design. Although this
method is capable of providing detailed information regard-
ing ligand binding and localization, there are significant
barriers to its implementation in a drug discovery setting.
Because SAR by NMR requires the iterative screening of
large compound libraries, hundreds of milligrams of 15N-
labeled protein must be produced, which is problematic
for drug targets that cannot be expressed to high levels in
bacterial cells. Moreover, the method may be used only
for smaller drug targets (up to 20–30 kDa), and requires
that the NMR assignment and structure determination for
the protein be completed before screening commences.
Such requirements are highly limiting, as the NMR struc-
ture of a 30 kDa protein is well beyond the reach of many
protein NMR labs, and, even in labs that are capable of
such a structure determination, by the time it is com-
pleted the information might be of little value. 
In many regards, the SHAPES strategy is of significantly
greater utility than SAR by NMR. For example, SHAPES
screening does not require isotopically labeled protein,
may be applied to proteins with no molecular weight limit,
and does not require that the structure of the target be
solved. The SHAPES strategy does not involve iterative
screens of large libraries, but rather a single screen of a
much smaller library, so requires significantly less protein,
which may be derived from either recombinant or natural
sources. A disadvantage of the SHAPES approach is that
although one can easily assess which small-molecule com-
pounds bind the target, one cannot tell where these com-
pounds bind. Follow-up experiments are needed to
determine whether binding occurs at an active site, and
whether the binding is specific. 
Of the above considerations, perhaps the most important
from a practical standpoint is target size. The SHAPES
strategy evolved as method for lead generation aimed at
larger molecular weight targets primarily because our in-
house drug targets were all very large by NMR standards.
Although deciding what makes a good drug target is a
highly subjective process, in our opinion there have been
only a handful of good drug targets of less than
20–30 kDa, making an approach like SAR by NMR,
despite its advantages, of limited utility. To address this
issue, other groups have also developed and used NMR
techniques that are capable of examining larger molecular
weight systems. For example, Meyer et al. [6] have used
transferred NOE techniques to examine binding of a
library of oligosaccharides to a protein target. In addition,
Hajduk et al. [5] have described methods using relaxation
and diffusion edited NMR difference methods to
examine mixtures of unlabeled ligands with unlabeled
target proteins.
Perhaps the greatest differences between SHAPES and
SAR by NMR are in their basic philosophies and objec-
tives. SAR by NMR is a very elegant but resource-inten-
sive method of designing very tight binding (nanomolar
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Figure 8
2D NOESY spectrum (τm = 80 ms) of a mixture of compounds with an
undisclosed target. Two SHAPES ligands in this mixture bind the target.
Intraligand cross peaks for VRT-13,578 are highlighted with blue boxes
in the downfield region of the spectrum, whereas intraligand NOEs for
VRT-19,962 are shown in white in the upfield region. Cross peaks
falling outside the boxes are interligand NOEs, implying that these
ligands bind in close proximity to one another. The screening sample
contained a 10:1 ratio of ligands to protein; 1 mM ligands + 100 µM
protein. Data were collected at 295 K with 1 s low power presaturation
of the residual HDO signal, using a Bruker DMX-500 spectrometer.
16 Scans were collected for each of 200 t1 increments. 1024 complex
points were collected in the t2 dimension. The t1 dimension was
expanded to 256 complex data points using linear prediction, then 
zero filled to 512 points before Fourier transformation.
affinity) inhibitors using NMR as the principal technology.
The goal of SHAPES screening and the subsequent
follow-up experiments is to establish one or more lead
classes of micromolar affinity compounds that may be opti-
mized using more efficient, higher throughput methods for
compound synthesis, screening and structure-based drug
design. We believe the latter methods are much better
suited for exploring the larger regions of chemical diversity
space necessary to maximize in vitro potency.
Implementation of the SHAPES strategy and
follow-up protocols
Given sufficient protein (or other target), SHAPES
screening is simple to implement and uses hardware
already found in a typical NMR lab. However, it is the
follow up to the SHAPES hits that makes the technique
versatile, and one can easily imagine different laboratories
using SHAPES data to complement existing in-house
technologies or expertise. For example, for a low molecu-
lar weight target that is amenable to SAR by NMR screen-
ing, SHAPES may be used as an inexpensive way to
identify binders initially. SHAPES hits or follow-ups from
HTS could then be examined using chemical shift pertur-
bation experiments with 15N-labeled protein to localize
the binding site and suggest modifications, or to carry out
optimization of additional subsites. 
In our research setting, SHAPES screening is a valuable
component of a discovery effort based on numerous bio-
physical and computational approaches. Experimental data
from SHAPES hits are integrated with computational
methods such as virtual screening, where databases of mol-
ecules, either real or virtual, are assessed according to their
synthetic accessibility, shape, flexibility, strain energy,
similarity to known leads, pharmacophores, docking scores
or other properties relevant for in vivo activity such as
LogP or metabolic stability [2]. NMR-based screening
methods may therefore be considered as an additional
‘filter’ in the process of virtual screening. 
What are the advantages of an approach to lead generation
combining NMR screening and computational protocols?
The virtual screening process becomes significantly more
information based; NMR screening has the potential for
identifying screening compounds predisposed towards
higher target affinity; starting the lead optimization
process with small, soluble binding cores could increase
the probability of a final drug candidate with an attractive
solubility profile; and starting with a diverse set of NMR
screening hits could result in a greater diversity of poten-
tial scaffolds. Having the flexibility of pursuing several
compound classes at once to identify active drug mol-
ecules provides a significant advantage in a preclinical dis-
covery program, where efforts often become trapped in a
local minimum in compound space. In this situation, one
typically has a compound with good in vitro potency but
poor pharmacokinetic or toxicological properties. Although
optimization of the pharmacokinetic properties might be
possible, it cannot be achieved without sacrificing in vitro
potency. Having several lead classes of micromolar
potency would be very useful in such a situation, and
would also be an advantage from the perspective of intel-
lectual property protection.
Figure 9 shows a comparison of the inhibitory landscape of
the SHAPES strategy with that of an approach based
solely on HTS of compound libraries. Figure 9a shows a
‘golf course’, or flat landscape with a very narrow window
into a maximum inhibitory potential. The flat landscape
arises because of the insensitivity of a typical HTS assay,
in which only inhibitors stronger than a certain threshold
in the low micromolar or high nanomolar range may be
detected. Alternatively, techniques like SHAPES are
capable of detecting weak binding inhibitors (Figure 9b),
and through subsequent activities such as screening of
follow-up libraries, virtual screening, or design of combi-
natorial libraries based on SHAPES hits, will follow a
more gradual descent into a hypothetical maximum
inhibitory potential. Of course, this is a radically oversim-
plified view of two different approaches to drug discovery,
and a more realistic landscape is shown in Figure 9c. This
landscape has several peaks and valleys indicating local
minima in compound space (i.e. trajectories from which a
global maximum with regard to inhibitory potential cannot
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Figure 9
Inhibitory landscapes illustrating the
conceptual approach to maximum inhibitory
potential in compound space using (a) high-
throughput screening and (b) SHAPES
screening. A more realistic picture, containing
peaks and valleys indicating local minima, is
shown in (c). These landscapes were
originally created by Dill and Chan [29] and
used to describe protein folding energy
landscapes. Images are used with permission.
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be approached without significantly changing chemical
composition). One should also note that compound space
is rarely regarded as a three-dimensional space, but rather
an N-dimensional space where one must optimize other
parameters aside from in vitro potency such as pharmaco-
kinetics, toxicology and solubility factors related to formu-
lation. Understanding compound space in such higher
dimensionality to guide compound selection remains a
major focus of research efforts for computational chemists
in drug discovery.
Significance
A new method for lead generation (SHAPES) is
described that uses simple NMR techniques to
detect binding of a limited but diverse library of low
molecular weight, soluble compounds to a potential
drug target. The NMR experiments, based on the well-
known techniques of differential line broadening
and transferred nuclear Overhauser enhancement
(tNOE), do not have a limitation on molecular weight
and do not require isotope labeling of the targets.
SHAPES library compounds are derived largely from
molecular frameworks most commonly found in
known therapeutic agents [3].
The SHAPES strategy is useful for identifying potential
lead classes of drugs early in a drug design program.
SHAPES screening may be easily integrated into a dis-
covery effort based on numerous biophysical and com-
putational approaches. Following screening, weak
binding (Kd ~µM–mM) hits, most of which would be
missed in a standard enzymological assay, may be used
to guide virtual screening of in-house or available com-
pound databases, guide synthesis of combinatorial
libraries, and bias the first compounds that undergo high-
throughput screening. Data derived from several in-house
drug discovery programs indicate that high-throughput
screening hit rates for follow-up compounds chosen on
the basis of an initial SHAPES screen are up to tenfold
higher than hit rates for compounds chosen randomly.
Binding data from SHAPES hits may also be used
advantageously in computational efforts such as virtual
screening, in which databases of molecules, either real
or virtual, are assessed according to their synthetic
accessibility, shape, pharmacophores, strain energy or
other properties.
To demonstrate the feasibility of such an approach, we
have screened the SHAPES library against a number of
drug targets. We were able to rapidly differentiate
between binding and nonbinding compounds in small
noninteracting mixtures, demonstrating the utility of the
method with several enzyme targets, including the
p38 MAP kinase, a 42 kDa protein, and inosine-5′-
monophosphate dehydrogenase, a multimeric enzyme
target of 224 kDa.
Materials and methods
NMR screening
Samples. Stock solutions of SHAPES compounds were made at con-
centrations of 100 mM or 500 mM in d-DMSO and stored at –20°C.
Reference NMR samples of individual compounds were made for each
target in the appropriate aqueous buffer system by adding stock solu-
tion such that final compound concentrations were 1 mM in 0.5 ml.
Mixture samples for p38 MAP kinase screening contained 1 mM
ligands, 0.2 mM p38 MAP kinase, 25 mM deutero-Tris, 10% deutero-
glycerol, 20 mM deutero-DTT at pD* = 8.4. Mixture samples for IMPDH
screening contained: 1 mM compound (1), 0.1 mM IMPDH, 25 mM
d-TRIS pD* = 8.4, 300 mM KCl, 5% d-glycerol, 5 mM DTT.
Design of mixtures. Experimental and computational protocols for
mixture design may be found the Supplementary material section.
NMR measurements. NMR screening for all targets were carried out
on a Bruker DMX 500 MHz spectrometer equipped with a sample
changer and automation control software from the vendor (IconNMR,
Bruker Instruments, Billerica, MA). 1D and 2D spectra were acquired at
277K (IMPDH) and 278K (p38 MAP kinase) using standard pulse
sequences and phase cycling. A 1D NOESY pulse sequence was
used for collection of 1D spectra due to better suppression of residual
HDO. Recycle delays were chosen to ensure sufficient relaxation for
the small molecule mixtures. 2D NOESY parameters were set to mini-
mize total experiment time yet contain adequate resolution in both
spectral dimensions. Details for individual experiments are given in the
Figure legends. Acquisition data was processed using vendor software
(XWinNMR 1.2, Bruker Instruments, Billerica, MA).
Reducing spectral contributions from the target protein. Relax-
ation filtering elements [21,22] in the pulse sequences can be used to
attenuate the protein signals. Thickening agents may also be used to
slow the molecular tumbling of the protein. Refer to the Supplementary
material section for details.
Kd determination by NMR diffusion measurements
The apparent diffusion coefficient of the SHAPES ligand in the pres-
ence of protein is a weighted average, determined by the relative
amounts of free and bound ligand. Specifically, if pb represents the
fraction of ligands that are bound to protein, then we can express the
observed diffusion coefficient as a specific case of the observable P
in equation 2:
Dapp = (1-pb)Dfree + pb(Dbound) (3)
where Dapp is the apparent diffusion coefficient of the SHAPES ligand
in the presence of protein, Dfree is diffusion coefficient of SHAPES
ligand by itself, and Dbound is the diffusion coefficient of the bound
ligand. This value is the same as that of the protein, and is readily mea-
sured. Using equation 3, we solve for the bound fraction, pb. Then, from
pb, we get the Kd using the well-known expression:
Kd = (Ltot/pb){pb2-pb(1 + Ptot/Ltot) + (Ptot/Ltot)} (4)
where Ltot is the total ligand concentration, and Ptot is the total
protein concentration.
The pulse sequences for measuring the diffusion included the water-
sLED pulse sequence [23], and a 1D PFG-TOCSY sequence [24]
employing bipolar gradients [25]. In both pulse sequences, molecular
diffusion occurring during the time between the phase-encoding and
phase-decoding gradients (or corresponding bipolar pairs in the
TOCSY sequence) attenuates the peak heights of the resulting
spectra. This attenuation is exacerbated with increasing gradient ampli-
tude. Denoting a given peak integral by I, the attenuation is described
by the decay:
I = A exp(-DK2) (5)
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In the above expression, D is the desired diffusion coefficient, A is the
peak integral in the absence of the two phase encoding/decoding gra-
dients, and K2 is a factor proportional to the square of the gradient
amplitude. In the case of the water-sLED sequence K2 = γ2δ2Gz2(∆-
δ/3) and for the 1D PFG-TOCSY, K2 = 4γ2δ2Gz2(∆ + (5δ/3)). In both
cases, γ = 1H gyromagnetic ratio, δ = gradient pulse length, G = gradi-
ent amplitude and ∆ = time delay between gradients (diffusion time).
Fitting a data file consisting of peak integrals versus K2 to equation 4
gives the diffusion coefficient, D, and the prefactor, A. The spin lock
between the phase-encoding and decoding bipolar gradient pairs in
the 1D-TOCSY pulse sequence provides additional relaxation filtering
of the protein signals, and is helpful for a better estimation of ligand dif-
fusion coefficients. Alternatively, the water-sLED experiment permits
longer diffusion waiting times, and is preferable for measuring smaller
diffusion coefficients, such as those of protein targets.
To maximize the percent of ligand bound to protein (pb), diffusion mea-
surements should be carried out with concentrations of protein and
ligand at close to equimolar ratios. For the example shown in Figure 5,
two NMR samples were prepared. One sample contained only 4-(3-
pyridin-4-yl-1H pyrazol-4-yl) pyrimidine at 0.5 mM ,and the other con-
tained both p38 and 4-(3-pyridin-4-yl-1H-pyrazol-4-yl) pyrimidine at
0.2 mM and 0.4 mM, respectively. As the diffusion experiments used
(1D PFG–TOCSY) involve Hahn spin-echo segments, in which
protein signals decay as R2, this provided a serendipitous relaxation
filter that suppressed most of the protein signals, with the exception of
some resolved aromatic resonances. Use of the TOCSY spinlock
further decreased protein resonance contributions. Appearance of
protein signals in the spectrum of the p38/4-(3-pyridin-4-yl-1H-
pyrazol-4-yl) pyrimidine sample, conveniently allowed measurement of
diffusion coefficients for both the protein (Db), and ligand (Df) from the
same sample.
Errors in Kd values calculated from the diffusion coefficients may arise
because of random errors or systematic errors arising from intermolec-
ular cross relaxation [26]. Small errors in D arising from either source,
can result in large errors in Kd. Errors due to chemical exchange effects
can be eliminated by use of bipolar gradients [27]. Errors due to cross
relaxation [26] can be minimized by working with short diffusion times.
Random errors cannot be eliminated and the effects of these errors
should be considered. For example, using elementary propagation of
errors and assuming that errors in the measured diffusion coefficients
are statistically independent and ~5%, we find in terms of fractional
error: 5% error in Da → 98% error in pb → 125% error in Kd, for
Kd = 1 mM; 5% error in Da → 20% error in pb → 57% error in Kd, for
Kd = 100 µM; 5% error in Da → 10% error in pb → 127% error in Kd,
for Kd = 10 µM.
Clearly, the fractional precision suffers at both low- and high-affinity
ends, but the absolute precision gets worse only for weaker binders.
Uncertainties in Kd will decrease or increase for lower and higher error
estimates, respectively, for Da, Db, and Df.
NMR diffusion experiments were carried out at 295 K on a Bruker
DRX-800 MHz spectrometer. All gradient pulses are rectangular
shaped and applied along the z-axis. The diffusion time, ∆, was 30 ms
and 148.5 ms for ligand and protein measurements, respectively. For
the free ligand and ligand–protein samples, 16 data sets were
recorded corresponding to increasing strengths of the phase encod-
ing/decoding gradients. Data sets for both samples were Fourier-trans-
formed using vendor software (XWinNMR 1.2, Bruker Instruments,
Billerica, MA). The resulting peaks were integrated and diffusion coeffi-
cients were determined by using the Levenburg–Marquardt algorithm
[28] to fit the integrals to equation 5. The 4-(3-pyridin-4-yl-1H-pyrazol-
4-yl) pyrimidine sample yielded Dfree = 0.294 ± 0.012 × 10–5 cm2/s. The
resolved ligand resonances of the p38/4-(3-pyridin-4-yl-1H-pyrazol-4-
yl) pyrimidine sample yielded Dapp = 0.229 ± 0.002 × 10–5 cm2/s,
whereas the resolved p38 aromatic resonances of the same sample
yielded Dbound = 0.053 ± 0.002 × 10–5 cm2/s. 
Selection of follow-up compounds
Pharmacophore-based search. A pharmacophore model was con-
structed using three structurally similar compounds for which only NMR
screening data were available. Models for the three-dimensional struc-
tures of the hits were constructed and minimized in Insight (version
950, Molecular Simulations, Inc.), and then overlapped using molecular
field similarity optimization. The models were first pre-aligned using
their moments of inertia, then superimposed using an equal combina-
tion of steric shape and electrostatic potential factors. A pharma-
cophore hypothesis was constructed, comprised of approximate
distances between a common aromatic centroid, aliphatic carbon, and
two hydrogen bond donors, from the superposition giving the highest
similarity score. Using this model, a three-dimensional substructure
search was then executed using Isis (v. 2.1.3, MDL Information
Systems, Inc.) against minimized structures from the ACD.
Structure-based searches. ACD compounds resembling the
screening hits were identified by performing substructure searches
(100% identity, permitting heteroatoms at selected sites) and similarity
searches (substructure search at 90% similarity, superstructure search
at 40–70% similarity) using Isis. Some screening hits possessed a
large number of commercially available analogs. In such cases, the
number of candidates was reduced by giving preference to com-
pounds containing sidechains commonly found in known drugs (see
Supplementary material section), particularly those conferring aqueous
solubility: carboxy, methoxy, hydroxy, N-methyl, amino, sulfo, carbonyl,
and CH2-OH .
Selection filters. The raw list of candidate compounds was subjected
to several stages of filtering. To remove compounds likely to interfere
with enzymatic assays (~20% of the total), highly colored compounds
(e.g. biological stains, industrial dyes), radioactives, and solutions (e.g.
forensic HPLC standards) were removed. Purchasing delays were min-
imized by purchasing only from a list of ten preferred vendors. To
remove compounds with non-drug-like properties, a REOS filter was
applied (REOS = rapid elimination of swill) [2], that incorporates rule of
five [17], MW, logP and functional group criteria [18]. Approximately
83% of the compounds from the ACD are eliminated by the filtering
process, most of them in the latter step.
Virtual follow-up screening analysis. In this analysis, HTS assay
data were used to model the results of hypothetical follow-up assays
for several enzyme targets. First, SHAPES screening was carried out,
and core scaffolds were identified for hits that have inhibitory activity
(typically yielding 5–6 classes of scaffolds). Previously collected
30 µM assay data (for between 1700 and 26,500 compounds) were
edited to remove compounds that appeared to interfere with the assay
(e.g. absorbed at the readout frequency of a colorimetric assay) or
gave more than 30% relative standard deviation between replicate
data points. In addition, the analysis was restricted to compounds that
passed the REOS filter, because only those compounds would actu-
ally be selected for a typical follow-up library. Separate analyses were
carried out by defining ‘hits’ as compounds with either 30% or 50%
inhibition at 30 µM. An Isis substructure search was then used to
identify the subset of compounds screened by HTS that contained
scaffolds from SHAPES inhibitors; these subsets comprised the
virtual follow-up libraries. The hit rates for the virtual follow-up libraries
were defined as the percentage of compounds that were hits in the
enzymatic assay. These hit rates were compared to those obtained for
the pooled set of all other compounds in order to compute the differ-
ence in the frequency of hits between SHAPES and non-SHAPES
derived compounds.
Supplementary material
Supplementary material including the frequence of occurrence for
sidechains most commonly found in drugs, details about the experi-
mental and computational protocols for mixture design and details
about reducing spectral contributions from the target protein is avail-
able at http://current-biology.com/supmat/supmatin.htm.
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